70O A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

Y.J. Lee; Y-Y. Lee; J C Park; H-W. Cho; M.C. Lim; M.K. Kim; J-M. Lee; E. Yang; J S Lee

doi:10.1016/j.esmoop.2026.108096

July 1, 2026ESMO OpenOpen Access

70O A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to explore the effectiveness of nivolumab as an induction treatment for patients with mismatch repair deficient endometrial cancer.
Phase II clinical trial examining patients with surgically completely resectable MMRd endometrial cancer.
Utilized nivolumab to induce immune response.
Focused on the immunogenic potential of MMRd tumors.
Demonstrated the high immunogenicity of MMRd tumors with nivolumab treatment.
Showed an induction of immune checkpoint blockade in patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase II study investigates induction PD-1 blockade in surgically resectable MMRd endometrial cancer, indicating a new treatment option.

Abstract

Mismatch repair deficiency (MMRd) tumors are known to be highly ImmunoGenic and of great interest for immune checkpoint inhibitor. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) in patients with surgically resectable MMRd endometrial cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a48a6b689561a0c2d78e93c https://doi.org/10.1016/j.esmoop.2026.108096

View Full Paper

Ask AI

Bookmark

Share

70O A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

70O A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading